More Bad News for Zetia and Vytorin
Regular readers will remember that I wrote about Zetia back in November. That post had some important background for this week's news, and a handy lesson about the difference between clinical and intermediate outcomes in medical studies. If you missed it, you may want to check it out. This week, Merck released the data from a stud...